NetworkNewsBreaks – Cytori Therapeutics, Inc. (NASDAQ: CYTX) Shares Nudge Higher on New Key Cell Therapy Platform Patents

Cytori Therapeutics (NASDAQ: CYTX) this morning said it has received key patents that strengthen its intellectual property portfolio in the U.S. and Europe, sending shares up 2% mid-morning. To date, the company has 107 global patents issued in addition to 45 patent applications pending approval. Many of the most recently issued patents contain claims regarding the use of the company’s Habeo™ Cell Therapy for patients with scleroderma affecting the hands. “Our intellectual property strategy is to continue to strengthen the Cytori Cell Therapy™ platform to help establish and maintain a sustainable competitive advantage. Our main focus is on the primary therapeutic targets of scleroderma and Raynaud’s Phenomenon, though we will continue to seek additional intellectual property in other therapeutic areas as well,” VP and general manager John D. Harris stated in the news release.

To view the full press release, visit:

About Cytori

Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point¬of¬care through Cytori’s proprietary technologies and products. Cytori Nanomedicine™ is developing liposome encapsulated therapies for regenerative medicine and oncologic indications. For more information, please visit

About NetworkNewsBreaks

NetworkNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s